Adimab and DNA2.0 Enter Exclusive Antibody Discovery Relationship
News Nov 16, 2007
Adimab, Inc., a pioneer in the integration of antibody discovery, maturation and biomanufacturing and DNA2.0, Inc. (Menlo Park, CA), the largest U.S. supplier of synthetic DNA today announce a strategic alliance in the area of antibody discovery.
The two companies have entered into an exclusive agreement to jointly develop and produce proprietary antibody libraries that replicate the human immune system’s ability to produce antibodies against any target.
“We did extensive diligence on the leading gene synthesis companies and DNA2.0 had an impeccable reputation amongst its customers. Their ability to work with us on the integration of all aspects of gene synthesis and library design was a major driver in this relationship,” says Dane Wittrup, Adimab co-founder and professor at MIT.
“Adimab brings a disruptive and novel approach to antibody discovery that has the potential to change the way we discover therapeutic antibodies in the future. We wanted to be part of that exciting development,” says Jeremy Minshull, DNA2.0 co-founder and president.
For more information, visit Adimab’s Partners
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019